165 related articles for article (PubMed ID: 36371345)
41. RAS mutation and associated risk of malignancy in the thyroid gland: An FNA study with cytology-histology correlation.
Gilani SM; Abi-Raad R; Garritano J; Cai G; Prasad ML; Adeniran AJ
Cancer Cytopathol; 2022 Apr; 130(4):284-293. PubMed ID: 34847284
[TBL] [Abstract][Full Text] [Related]
42. Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review.
Hier J; Avior G; Pusztaszeri M; Krasner JR; Alyouha N; Forest VI; Hier MP; Mlynarek A; Richardson K; Sadeghi N; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2021 Apr; 50(1):29. PubMed ID: 33910629
[TBL] [Abstract][Full Text] [Related]
43. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
[TBL] [Abstract][Full Text] [Related]
44. Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations?
Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
Cytopathology; 2021 Jan; 32(1):37-44. PubMed ID: 32803788
[TBL] [Abstract][Full Text] [Related]
45. RAS Mutations in AUS/FLUS Cytology: Does it Have an Additional Role in BRAFV600E Mutation-Negative Nodules?
Yoon JH; Kwon HJ; Lee HS; Kim EK; Moon HJ; Kwak JY
Medicine (Baltimore); 2015 Jul; 94(27):e1084. PubMed ID: 26166089
[TBL] [Abstract][Full Text] [Related]
46. Does the likelihood of malignancy in thyroid nodules with RAS mutations increase in direct proportion with the allele frequency percentage?
Hudson TJ; Pusztaszeri MP; Hier MP; Forest VI; Yang JW; Payne RJ
J Otolaryngol Head Neck Surg; 2023 Feb; 52(1):12. PubMed ID: 36774522
[TBL] [Abstract][Full Text] [Related]
47. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
[TBL] [Abstract][Full Text] [Related]
48. Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next?
Yoo MR; Gweon HM; Park AY; Cho KE; Kim JA; Youk JH; Son EJ
PLoS One; 2015; 10(6):e0130138. PubMed ID: 26115096
[TBL] [Abstract][Full Text] [Related]
49. Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules.
Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
World J Surg; 2020 Jul; 44(7):2264-2271. PubMed ID: 32227276
[TBL] [Abstract][Full Text] [Related]
50. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract][Full Text] [Related]
51. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.
Labourier E; Shifrin A; Busseniers AE; Lupo MA; Manganelli ML; Andruss B; Wylie D; Beaudenon-Huibregtse S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2743-50. PubMed ID: 25965083
[TBL] [Abstract][Full Text] [Related]
52. Molecular analysis of residual ThinPrep material from thyroid FNAs increases diagnostic sensitivity.
Krane JF; Cibas ES; Alexander EK; Paschke R; Eszlinger M
Cancer Cytopathol; 2015 Jun; 123(6):356-61. PubMed ID: 25926393
[TBL] [Abstract][Full Text] [Related]
53. UTILITY OF ULTRASOUND VERSUS GENE EXPRESSION CLASSIFIER IN THYROID NODULES WITH ATYPIA OF UNDETERMINED SIGNIFICANCE.
Villabona CV; Mohan V; Arce KM; Diacovo J; Aggarwal A; Betancourt J; Amer H; Jose T; DeSantis P; Cabral J
Endocr Pract; 2016 Oct; 22(10):1199-1203. PubMed ID: 27409819
[TBL] [Abstract][Full Text] [Related]
54. Assessment of molecular testing in fine-needle aspiration biopsy samples: an experience in a Chinese population.
Liu S; Gao A; Zhang B; Zhang Z; Zhao Y; Chen P; Ji M; Hou P; Shi B
Exp Mol Pathol; 2014 Oct; 97(2):292-7. PubMed ID: 25111330
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic Lobectomy for Bethesda III Thyroid Nodules: Pathological Outcomes and Risk Factors for Malignancy.
Walters BK; Garrett SL; Aden JK; Williams GM; Butler-Garcia SL; Newberry TR; Mckinlay AJ
Ann Otol Rhinol Laryngol; 2021 Sep; 130(9):1064-1068. PubMed ID: 33567896
[TBL] [Abstract][Full Text] [Related]
56. Can TP53-mutant follicular adenoma be a precursor of anaplastic thyroid carcinoma?
Nikitski AV; Nikiforova MN; Yip L; Karslioglu-French E; Carty SE; Nikiforov YE
Endocr Relat Cancer; 2021 Aug; 28(9):621-630. PubMed ID: 34264855
[TBL] [Abstract][Full Text] [Related]
57. Indeterminate nodules by the Bethesda system for reporting thyroid cytopathology in Israel: Frequency, and risk of malignancy after reclassification of follicular thyroid neoplasm with papillary-like features.
Rosenblum RC; Shtabsky A; Marmor S; Trejo L; Yaish I; Barnes S; Yehuda M; Stern N; Silman Z; Tordjman KM
Eur J Surg Oncol; 2019 Jul; 45(7):1182-1187. PubMed ID: 30928335
[TBL] [Abstract][Full Text] [Related]
58. Thyroid Ultrasound-Guided Fine-Needle Aspiration Cytology Results: Observed Increase in Indeterminate Rate over the Past Decade.
Manning AM; Yang H; Falciglia M; Mark JR; Steward DL
Otolaryngol Head Neck Surg; 2017 Apr; 156(4):611-615. PubMed ID: 28118554
[TBL] [Abstract][Full Text] [Related]
59.
Sfreddo HJ; Koh ES; Zhao K; Swartzwelder CE; Untch BR; Marti JL; Roman BR; Dublin J; Wang RS; Xia R; Cohen JM; Xu B; Ghossein R; Givi B; Boyle JO; Tuttle RM; Fagin JA; Wong RJ; Morris LGT
Thyroid; 2024 Apr; 34(4):450-459. PubMed ID: 38407967
[No Abstract] [Full Text] [Related]
60. Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma.
Evranos B; Polat SB; Baser H; Ozdemir D; Kilicarslan A; Yalcin A; Ersoy R; Cakir B
Cytopathology; 2017 Aug; 28(4):259-267. PubMed ID: 27666595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]